RE:RE:RE:RE:Interim Datas and speculationsitntdf,
Well, the web site should be accurate.
Clearly, AN would have to pay royalties on all sales, so it is not a loss.
However, if a deal is made with Roche, say. to market a combo of pela, tecentiq and chemo, that would get a different name as I understand it. Then it seems like it would not be covered by the licence to AN.